Sandbox endocarditis: Difference between revisions
No edit summary |
|||
Line 501: | Line 501: | ||
*Quinupristin-dalfopristin only effective against E faecium and can cause severe myalgias, which may require discontinuation of therapy | *Quinupristin-dalfopristin only effective against E faecium and can cause severe myalgias, which may require discontinuation of therapy | ||
*Only small no. of patients have reportedly been treated with imipenem/cilastatin-ampicillin or ceftriaxone + ampicillin. | *Only small no. of patients have reportedly been treated with imipenem/cilastatin-ampicillin or ceftriaxone + ampicillin. | ||
|- | |||
|} | |||
|} | |||
|} | |||
==Staphylococci== | |||
{| | |||
| valign=top | | |||
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;"> | |||
<font color="#FFF"> | |||
'''Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table23" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table24" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity in the Absence of Prosthetic Material''' | |||
</font> | |||
</div> | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table23" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material}} | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] or [[Oxacillin]] † 12 g I.V. daily in equally divided doses x 6 Wks ''''' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS (optional) | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin|Gentamicin sulfate]] ‡ 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days ''''' | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Altenative Regimen</u>'''''( in non anaphylactoid [[Penicillin]] hypersensitivity) | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefazolin]] 6 g/ 24 h I.V. in 3 divided doses x 6 wks ''''' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | PLUS (optional) | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg per 24 h IV/IM in 2-3 equally divided doses x 3-5 days ''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatrics dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] or [[oxacillin]] 200 mg/kg per 24 h IV in 4–6 equally divided doses x 4-6 wks'''''<BR>''OR ( in non anaphylactoid [[Penicillin]] hypersensitivity)'' <BR> ▸'''''[[Cefazolin]] 100 mg/kg per 24 h IV in 3 equally divided doses x 4-6 wks''''' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | AND (optional) | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 3 mg/kg per 24 h IV/IM in 3 equally divided doses''''' | |||
|- | |||
| | |||
:† Penicillin G 24 million U/24 h IV in 4 to 6 equally divided doses may be used in place of nafcillin or oxacillin if strain is penicillin susceptible (MIC ≤ 0.1 μg/mL) and does not produce β-lactamase. | |||
:‡ Gentamicin should be administered in close temporal proximity to vancomycin, nafcillin, or oxacillin dosing. | |||
|- | |||
|} | |||
|} | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table24" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Staphylococci (Methicillin-resistant) in the Absence of Prosthetic Material (in anaphylactoid Penicillin hypersensitivity)}} | |||
|- | |||
!style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | '''''<u>Preferred Regimen</u>''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
! style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30 mg/kg per 24 h IV in 2 equally divided doses x 6 wks''''' <br> Adjust vancomycin dosage to achieve 1-h serum concentration of 30–45 > g/mL and trough concentration of 10–15 >g/mL | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatrics dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 40 mg/kg per 24 h IV in 2 or 3 equally divided doses x 6 wks ''''' | |||
|- | |- | ||
|} | |} | ||
|} | |} | ||
|} | |} |
Revision as of 20:21, 5 March 2014
Streptococci
▸ Click on the following categories to expand treatment regimens.
Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus bovis ▸ Viridans Group Streptococci and Streptococcus bovis Highly Penicillin-Susceptible ▸ Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL) Prosthetic Valves Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin-Susceptible Strain (MIC ≤ 0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin Relatively or Fully Resistant Strain (MIC >0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml) ▸ Relatively Penicillin-Resistant Streptococci (MIC > 0.5 µg/ml) ▸ Unable to tolerate Penicillin or Ceftriaxone |
|
|
|
|
|
|
|
Enterococci
Endocarditis Caused by Enterococci ▸ Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin ▸ Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin ▸ Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin ▸ Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin |
|
|
|
|
Staphylococci
Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material ▸ Staphylococci (Methicillin Susceptible) in the Absence of Prosthetic Material ▸ Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity in the Absence of Prosthetic Material |
|
|